Week in Review: Recognizing the Value of New Medicines

03.29.13 | By

This week, many of our Catalyst posts explored the value of medicinal development and its ability to improve the lives of patients. Although moving new drugs through the rigorous approval process is expensive and time consuming, several major triumphs for scientists and clinicians recently verified the value of investing in innovative research and development, citing the long-term human and economic benefits.

New Medicines Offer Benefits

03.29.13 | By

As I skim the new report “Medicines in Development for Older Americans,” I’m reminded how new medications that are still being developed and clinically tested have already begun to have positive impacts on patients and local economies all over the country.

The Need for New Antibiotics

03.28.13 | By

Dr John H Rex, VP and Head of Infection, Global Medicines Development at AstraZeneca, recently spoke about the dangers of antimicrobial resistance on National Public Radio’s “To The Point” show, during which he noted that he is terrified at the pro

Rx Response

03.28.13 | By

Rx Response  – an initiative by members of the pharmaceutical supply chain designed to keep medicines moving to patients in emergencies like a natural disasters – got some welcome recognition at the 2013 National Hurricane Conference in New Orleans this week.   RxResponse Director and PhRMA Associate Vice President, Erin Mullen, PhD., RPh, CEM, was recognized

Huge Gains for Cancer Prediction

03.27.13 | By

A new cancer study is all over the news today, highlighting a batch of cancer “markers” that can help predict the disease earlier than before. It’s a testament to both how far we’ve come in our research to predict and treat cancer, and further how far we’ve got to go in finding a cure.

A Diabetes Wake Up Call

03.26.13 | By

Today is the American Diabetes Association Alert Day, a one-day, "wake-up call" asking the American public to take the Diabetes Risk Test to find out if they are at risk for developing type 2 diabetes. One in three American adults - that's 79 million people- have pre-diabetes, which puts them at high risk for developing type 2 diabetes. Not to mention the 26 million Americans that already have diabetes, a quarter of whom are unaware they have the disease.

Clinical Trials Report Unveiled in Texas

03.26.13 | By

Dr. Curtis Triplett, an assistant professor of diabetes medicine at the University of Texas Health Science Center at San Antonio Texas Diabetes Institute, is a clinician on the front lines of the fight against diabetes.

IP Protection Support Strong in the Congress

03.26.13 | By

Last week Senate Finance Committee Chair, Max Baucus (D. MT), and Ranking Member Orrin Hatch (R. UT) took a strong stand urging that the Administration secure robust intellectual property (IP) standards in the Trans-Pacific Partnership (TPP). In a letter to Ambassador Demetrios Marantis, Acting U.S.

Patent Settlements

03.25.13 | By

The Supreme Court heard arguments today in the case of Federal Trade Commission v.

"Fixing Cancer"

03.25.13 | By

If we really want to "fix cancer," as Ezekiel Emanuel and a group of oncologists suggested in the New York Times this weekend, we should focus on how we can continue to build on medical innovation collaborations that can lead to better scientific knowledge and discovery of targeted treatments that can help defeat this complex disease.


Subscribe to RSS - Opinion